Form 8-K AMARIN CORP PLC\UK For: May 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Strong earthquake rocks north-central Venezuela, capital Caracas
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Amarin Corp plc (AMRN) Misses Q1 EPS by 5c
May 8, 2015 6:10 AM EDTAmarin Corp plc (NASDAQ: AMRN) reported Q1 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $15.6 million versus the consensus estimate of $21.86 million.
Commercialization update - United States
Normalized prescriptions (estimated) for the first quarter of 2015, based on data from Symphony Health Solutions and IMS Health, totaled approximately 154,000 and 137,000, respectively. These prescription levels represent growth of approximately 5% for each data set compared to the quarter ended December 31, 2014, and an increase of approximately 66% and 76%, respectively, compared to the same quarter in 2014.
Revenue and... More
Amarin Corp plc (AMRN) to Resume Trading at 4:45
May 7, 2015 4:19 PM EDTAmarin Corp plc (NASDAQ: AMRN) to Resume Trading at 4:45
... MoreAmarin (AMRN) Files Suit Against FDA Related to Off-Label Promotion
May 7, 2015 4:18 PM EDTAmarin Corp plc (NASDAQ: AMRN) and four independent physicians, in support of improved patient care, filed a lawsuit to permit Amarin to share truthful and non-misleading information with healthcare professionals in the United States that would be considered off-label by the Food and Drug Administration (FDA). The lawsuit, captioned Amarin Pharma, Inc., et al. v. Food & Drug Administration, et al., was filed in the United States District Court for the Southern District of New York. It seeks a judicial declaration that FDA regulations limiting off-label promotion of such truthful and non-misleading information are... More
